Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT20plus: Biomarker-driven Therapy in Melanoma
NCT05063058Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2016
- Primary completion
- Nov 2019
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of trametinib, selumetinib, crizotinib, cabozantinib, sorafenib and 2 more in melanoma, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Number of patients with actionable molecular alterations at 5 years, Number of patients with a treatment recommendation at 5 years and 1 more. Started Jan 2016; status: completed.
02
Drugs
trametinibselumetinibcrizotinibcabozantinibsorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05063058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063058.